Goodbye to Alzheimer'

A promising exploratory treatment for Alzheimer's malady

Based on a U.S. study, two clinical trials around a nontoxic molecule are launched with 3000 participants. Treatment could be sold within the next two to three years

An experimental treatment for Alzheimer's disease has proved potentially promising and without toxic effects, according to the results of a small clinical trial published Wednesday. A drug may be placed on the market within the next two to three years

The study, published in the American medical journal Science Translational Medicine, opened the way to two more extensive clinical trials are underway with nearly 3000 participants.

A molecule, called verubecestat, developed by the American Merck laboratories, reduced the presence of toxic protein beta-amyloid in the brain by blocking an enzyme called BACE1.

In Alzheimer's disease, an incurable neurological degeneration associated with aging, these proteins form plates in this shadowy, which alters the functioning of neurons, affecting cognitive abilities including especially memory.

Treatments already on the market to treat Alzheimer's disease to minimize symptoms of the disease, but none are yet able to stop it or slow its progression.

Clinical trials will be concluded in July 2017

32 the first small clinical trial participants suffered from Alzheimer's disease at early and moderately advanced stages.

Unlike other molecules neutralizing the BACE1 enzyme, developed and tested previously, the verubecestat is not toxic. So she did not cause liver and neurological side effects severe, explains Matthew Kennedy, of the laboratory 

Research of Merck in New Jersey. The researchers measured the effects of this molecule and found that one or more doses of verubecestat could lower harmful levels of beta-amyloid.

Two international clinical trials, called phase 3, to assess the clinical effectiveness of the verubecestat will be completed in July 2017. If the results are conclusive, this treatment in the form of tablets could be placed on the market within the next two to three years.

As indicated by the World Health Organization, more than 36 million individuals worldwide are living with dementia, has a populace of Alzheimer's malady. This number is relied upon to twofold by 2030 and triple by 2050 if no successful treatment is found..